PI3K-alpha inhibitor - Akylox Therapeutics
Alternative Names: Covalent PI3K-alpha inhibitorLatest Information Update: 13 Mar 2026
At a glance
- Originator Akylox Therapeutics
- Class Antineoplastics
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 13 Mar 2026 Preclinical trials in Cancer in Denmark (PO) prior to March 2026